BFM
ADMA icon

Boothbay Fund Management’s ADMA Biologics ADMA Stock Holding History

Boothbay Fund Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.85M Buy
1,176,682
+184,799
+19% +$1.68M 0.13% 169
2026
Q1 		$8.94M Buy
991,883
+203,531
+26% +$3.21M 0.12% 164
2025
Q4 		$14.4M Buy
788,352
+15,194
+2% +$256K 0.21% 80
2025
Q3 		$11.3M Buy
+773,158
New +$13.3M 0.16% 134
2024
Q3 		– Sell
-493,311
Closed -$5.52M – 1577
2024
Q2 		$5.52M Sell
493,311
-293,496
-37% -$2.46M 0.13% 202
2024
Q1 		$5.19M Sell
786,807
-302,899
-28% -$1.66M 0.1% 213
2023
Q4 		$4.93M Buy
1,089,706
+44,494
+4% +$165K 0.13% 201
2023
Q3 		$3.74M Buy
1,045,212
+31,375
+3% +$121K 0.09% 303
2023
Q2 		$3.74M Sell
1,013,837
-220,667
-18% -$818K 0.08% 328
2023
Q1 		$4.09M Buy
1,234,504
+183,119
+17% +$633K 0.08% 331
2022
Q4 		$4.08M Sell
1,051,385
-7,069,768
-87% -$21.8M 0.09% 296
2022
Q3 		$19.7M Sell
8,121,153
-2,239,247
-22% -$5.37M 0.49% 12
2022
Q2 		$20.5M Sell
10,360,400
-47,859
-0.5% -$94.2K 0.54% 7
2022
Q1 		$19M Buy
10,408,259
+2,124,399
+26% +$3.31M 0.44% 21
2021
Q4 		$11.7M Buy
8,283,860
+5,153,324
+165% +$6.77M 0.27% 59
2021
Q3 		$3.54M Buy
3,130,536
+2,903,067
+1,276% +$4.07M 0.1% 251
2021
Q2 		$364K Buy
227,469
+24,385
+12% +$42.9K 0.01% 1168
2021
Q1 		$357K Buy
203,084
+59,549
+41% +$136K 0.01% 1113
2020
Q4 		$280K Buy
143,535
+53,453
+59% +$112K 0.01% 976
2020
Q3 		$215K Buy
90,082
+1,582
+2% +$4.34K 0.01% 932
2020
Q2 		$259K Sell
88,500
-62,243
-41% -$179K 0.02% 737
2020
Q1 		$434K Buy
+150,743
New +$521K 0.04% 479

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Boothbay Fund Management's ADMA Position: Q2 2026 in Review

Boothbay Fund Management increased its ADMA Biologics (ADMA) stake by 19% in Q2 2026, buying an estimated $1.68M and bringing the position to 1,176,682 shares worth $9.85M. The position accounts for 0.13% of the portfolio, ranked #169.

Boothbay Fund Management first reported a position in ADMA in Q1 2020 and has held it in 22 quarters since. The position peaked at $20.5M in Q2 2022. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Boothbay Fund Management held 1,176,682 shares of ADMA Biologics worth $9.85M as of Q2 2026.
  • Boothbay Fund Management bought 184,799 ADMA Biologics shares in Q2 2026, an estimated $1.68M.
  • ADMA Biologics made up 0.13% of Boothbay Fund Management's portfolio in Q2 2026, its #169 holding.
  • Boothbay Fund Management first reported a position in ADMA Biologics in Q1 2020 and has held it in 22 quarters since.
  • Boothbay Fund Management's ADMA Biologics position peaked at $20.5M in Q2 2022.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.